<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05043688</url>
  </required_header>
  <id_info>
    <org_study_id>LS2160</org_study_id>
    <nct_id>NCT05043688</nct_id>
  </id_info>
  <brief_title>A Trial Of Neoadjuvant Chemotherapy or Radiochemotherapy With Or Without SHR-1210 In Patients With Resectable ESCC.</brief_title>
  <official_title>A Trial Of Neoadjuvant Chemotherapy or Radiochemotherapy With Or Without SHR-1210 In Patients With Locally Advanced Resectable Esophageal Squamous Cell Carcinoma.This is a Randomised, Open, Parallel Control, Multi-center Phase II Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhigang Li</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Chest Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to explore the effectiveness and safety of neoadjuvant immune&#xD;
      combined chemotherapy or radiochemotherapy compared with traditional neoadjuvant&#xD;
      radiochemotherapy in patients with locally advanced Esophageal Squamous Cell Carcinoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 14, 2021</start_date>
  <completion_date type="Anticipated">March 6, 2026</completion_date>
  <primary_completion_date type="Anticipated">September 14, 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pCR</measure>
    <time_frame>within 14 working days after surgery</time_frame>
    <description>pCR is defined as pathological complete response(ypT0N0)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>approximately 22 months</time_frame>
    <description>OS is defined as the time from registration to death due to any cause, or censored at date last known alive. Measured by the method of Kaplan and Meier</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>R0 resection rate</measure>
    <time_frame>within 14 working days after operation</time_frame>
    <description>defined as complete resection rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EFS</measure>
    <time_frame>approximately 15 months</time_frame>
    <description>defined as event free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DFS</measure>
    <time_frame>approximately 15 months</time_frame>
    <description>defined as disease free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of completion of neoadjuvant treatment</measure>
    <time_frame>approximately 2 months</time_frame>
    <description>defined as proportion of completion of neoadjuvant treatment;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of completed operations for neoadjuvant treatment</measure>
    <time_frame>approximately 3 months</time_frame>
    <description>defined as proportion of completed operations for neoadjuvant treatment;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients progressing during neoadjuvant therapy;</measure>
    <time_frame>approximately 2 months</time_frame>
    <description>defined as the proportion of patients progressing during neoadjuvant therapy;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HRQoL</measure>
    <time_frame>approximately 48 months</time_frame>
    <description>defined as quality and nutrition assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AE</measure>
    <time_frame>approximately 48 months</time_frame>
    <description>adverse events</description>
  </secondary_outcome>
  <other_outcome>
    <measure>PD-L1 expression</measure>
    <time_frame>approximately 48 months</time_frame>
    <description>explore the correlation between the expression of PD-L1 and outcomes</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">204</enrollment>
  <condition>Locally Advanced Resectable Esophageal Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Neoadjuvant Chemotherapy With SHR-1210</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Neoadjuvant Chemotherapy： Paclitaxel（Albumin Bound）100mg/m2, Day 1,8,15，Carboplatin AUC=5mg/ml/min，Day 1，SHR-1210 200mg，Day 1，every 3 weeks, 2 cycles.&#xD;
Postoperative adjuvant treatment：SHR-1210 maintenance</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neoadjuvant Radiochemotherapy With SHR-1210</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Neoadjuvant Radiochemotherapy： Paclitaxel 50mg/m2, Day 1,8,15,22,29，Carboplatin AUC=2mg/ml/min，Day 1,8,15,22,29，SHR-1210 200mg，Day 1,22, 5 cycles.&#xD;
Radio therapy d1-23. Postoperative adjuvant treatment：SHR-1210 maintenance</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neoadjuvant Radiochemotherapy Without SHR-1210</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Neoadjuvant Radiochemotherapy： Paclitaxel 50mg/m2, Day 1,8,15,22,29，Carboplatin AUC=2mg/ml/min，Day 1,8,15,22,29， 5 cycles.&#xD;
Radio therapy d1-23. Postoperative adjuvant treatment：according to the recommendations of the guidelines and the investigators</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR-1210</intervention_name>
    <description>The study perform preoperative neoadjuvant therapy, surgery and postoperative adjuvant therapy on subjects. Preoperative neoadjuvant therapy includes 3 groups: immunotherapy combined with neoadjuvant chemotherapy, immunotherapy combined with neoadjuvant radiochemotherapy, and neoadjuvant radiochemotherapy.</description>
    <arm_group_label>Neoadjuvant Chemotherapy With SHR-1210</arm_group_label>
    <arm_group_label>Neoadjuvant Radiochemotherapy With SHR-1210</arm_group_label>
    <arm_group_label>Neoadjuvant Radiochemotherapy Without SHR-1210</arm_group_label>
    <other_name>paclitaxel</other_name>
    <other_name>carboplatin</other_name>
    <other_name>paclitaxel(albumin bound)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The result of pathological biopsy showed esophageal squamous cell carcinoma;&#xD;
&#xD;
          2. Have not received systemic or local treatment for esophageal cancer in the past;&#xD;
&#xD;
          3. Age 18-75 years (including 18 and 75 years old), both male and female;&#xD;
&#xD;
          4. ECOG score 0-1;&#xD;
&#xD;
          5. Thoracic esophageal cancer assessed by CT/MRI/EUS etc. as resectable and the clinical&#xD;
             stage is T1b-3N1-3M0 or T3N0M0, according to the 8th edition of AJCC staging;&#xD;
&#xD;
          6. Those who are expected to achieve R0 resection;&#xD;
&#xD;
          7. Voluntarily sign an informed consent form before treatment;&#xD;
&#xD;
          8. Plan to receive surgical treatment after neoadjuvant treatment is completed;&#xD;
&#xD;
          9. No surgical contraindications;&#xD;
&#xD;
         10. Normal function of major organs&#xD;
&#xD;
         11. Female subjects with fertility must undergo a serum pregnancy test within 72 hours&#xD;
             before starting the study drug administration, and the result is negative, and take&#xD;
             effective contraception during the trial and at least 3 months after the last&#xD;
             administration Measures (such as intrauterine devices, contraceptives, or condoms);&#xD;
             for male subjects whose partners are females of childbearing age, effective&#xD;
             contraceptive measures should be taken during the trial and within 3 months after the&#xD;
             last administration;&#xD;
&#xD;
         12. The subjects have good compliance and can follow up the efficacy and adverse&#xD;
             events/reactions according to the requirements of the plan;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. There are unresectable factors, including unresectable tumors, unresectable&#xD;
             contraindications for surgery, or rejection of surgery;&#xD;
&#xD;
          2. Patients with supraclavicular lymph node metastasis;&#xD;
&#xD;
          3. Poor nutritional status, BMI &lt;18.5 Kg/m2; if the symptomatic nutritional support is&#xD;
             corrected before randomization, the main investigator can continue to consider it&#xD;
             after evaluation;&#xD;
&#xD;
          4. Those who are known to have a history of allergies to the drug components of this&#xD;
             program;&#xD;
&#xD;
          5. Have received or are receiving any of the following treatments in the past:&#xD;
&#xD;
               1. Any radiotherapy, chemotherapy or other anti-tumor drugs for tumors;&#xD;
&#xD;
               2. Immunosuppressive drugs or systemic hormone drugs are being used within 2 weeks&#xD;
                  before the first use of the study drug to achieve immunosuppressive purposes&#xD;
                  (dose&gt;10mg/day prednisone or equivalent dose); if there is no active autoimmune&#xD;
                  disease In the case of inhalation or topical use of steroids and prednisone&#xD;
                  doses&gt; 10 mg/day or equivalent doses of adrenal cortex hormone replacement are&#xD;
                  allowed;&#xD;
&#xD;
               3. Received a live attenuated vaccine within 4 weeks before using the study drug for&#xD;
                  the first time;&#xD;
&#xD;
               4. Have undergone major surgery or severe trauma within 4 weeks before using the&#xD;
                  study drug for the first time;&#xD;
&#xD;
          6. A history of immunodeficiency, including a positive HIV test, or other acquired or&#xD;
             congenital immunodeficiency diseases, or a history of organ transplantation or&#xD;
             allogeneic bone marrow transplantation;&#xD;
&#xD;
          7. There are clinical symptoms or diseases of the heart that are not well controlled;&#xD;
&#xD;
          8. Severe infections (CTCAE v5.0&gt; level 2) occurred within 4 weeks before the first use&#xD;
             of the study drug, such as severe pneumonia, bacteremia, infectious comorbidities that&#xD;
             require hospitalization, etc.; baseline chest imaging examinations suggest activity&#xD;
             Pulmonary inflammation, symptoms and signs of infection in the 14 days before the&#xD;
             first use of the study drug, or those who require oral or intravenous antibiotic&#xD;
             treatment, except for the prophylactic use of antibiotics;&#xD;
&#xD;
          9. Participated in other drug clinical studies within 4 weeks before randomization;&#xD;
&#xD;
         10. People who are currently accompanied by interstitial pneumonia or interstitial lung&#xD;
             disease, or have a history of interstitial pneumonia or interstitial lung disease that&#xD;
             requires hormone therapy, or have other pulmonary fibrosis that may interfere with the&#xD;
             judgment and management of immune-related lung toxicity , Organizing pneumonia (such&#xD;
             as bronchiolitis obliterans), pneumoconiosis, drug-related pneumonia, idiopathic&#xD;
             pneumonia, or subjects whose CT shows active pneumonia or severe lung dysfunction&#xD;
             during the screening period; active tuberculosis;&#xD;
&#xD;
         11. Patients with any active autoimmune diseases or history of autoimmune diseases with&#xD;
             the possibility of recurrence; patients with skin diseases that do not require&#xD;
             systemic treatment, such as leukoplakia, psoriasis, hair loss, and insulin treatment&#xD;
             Patients with controllable type I diabetes or a history of asthma, but who have been&#xD;
             completely relieved during childhood without any intervention can be included in the&#xD;
             group; patients with asthma who need bronchodilator intervention cannot be included in&#xD;
             the group;&#xD;
&#xD;
         12. There is active hepatitis B (HBV-DNA ≥ 2000 IU/mL or 104 copies/mL), hepatitis C&#xD;
             (hepatitis C antibody is positive, and HCV-RNA is higher than the lower limit of the&#xD;
             analytical method);&#xD;
&#xD;
         13. Other malignant tumors have been diagnosed within 5 years before the first use of the&#xD;
             study drug, unless malignant tumors with low risk of metastasis or death (5-year&#xD;
             survival rate&gt; 90%), such as fully treated skin basal cell carcinoma or squamous cell&#xD;
             Skin cancer or cervical carcinoma in situ, etc., may be considered for inclusion;&#xD;
&#xD;
         14. Women who are pregnant or breastfeeding;&#xD;
&#xD;
         15. According to the judgment of the investigator, there are other factors that may lead&#xD;
             to the forced termination of the study, such as suffering from other serious diseases&#xD;
             (including mental illness) requiring combined treatment, alcoholism, drug abuse,&#xD;
             family or social factors, which may affect the subjects Factors of safety or&#xD;
             compliance.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jin Yan</last_name>
    <phone>18906495424</phone>
    <email>jin.yan@hengrui.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai Chest Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yang Yang</last_name>
    </contact>
    <investigator>
      <last_name>Zhigang Li</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://prsinfo.clinicaltrials.gov/results_definitions.html</url>
    <description>ClinicalTrials.gov Results Data Element Definitions for Interventional and Observational Studies (相关术语定义)</description>
  </link>
  <link>
    <url>http://prsinfo.clinicaltrials.gov/results_table_layout/ResultSimpleForms.html</url>
    <description>Checklists, templates, and examples to help gather information needed to report results to ClinicalTrials.gov (试验结果填写指南)</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 5, 2021</study_first_submitted>
  <study_first_submitted_qc>September 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 14, 2021</study_first_posted>
  <last_update_submitted>September 5, 2021</last_update_submitted>
  <last_update_submitted_qc>September 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Chest Hospital</investigator_affiliation>
    <investigator_full_name>Zhigang Li</investigator_full_name>
    <investigator_title>chief physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Esophageal Squamous Cell Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

